By: IPP Bureau
Last updated : June 01, 2026 6:55 pm
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
The leading CAR-T company T-CURX has signed definitive agreement for the acquisition of Pantherna Therapeutics, a German biotechnology company specializing in mRNA engineering and lipid nanoparticle (LNP) delivery technologies.
Pantherna will continue to operate as Pantherna Therapeutics as a wholly owned subsidiary of T-CURX. The complementary expertises and proprietary technologies of both companies will be leveraged to accelerate clinical translation of CAR-T strategies with a clear focus on clinical validation of in vivo CAR-T therapies.
T-CURX is a Würzburg-headquartered private biotech company with an additional site in Munich with strong expertise, proprietary technologies and track record for clinical translation of non-viral, transposon-based CAR-T therapies for novel and differentiated targets.
The company is backed by private investors and an international syndicate of blue-chip Biotech investors led by Swiss BiomedVC. T-CURX closed a USD 20.5 million Series A financing round at the end of 2025.
Pantherna was supported by a group of private investors and Germany-based High-Tech Gründerfonds (HTGF), who will become new shareholders of T-CURX. Financial terms of the transaction are not disclosed.
“With this acquisition, we are bringing together two highly complementary technology platforms and teams. We are taking a decisive step forward to accelerate the clinical development of differentiated, next-generation in vivo CAR-T therapies,” said Ulf Grawunder, CEO and co-founder of T-CURX.
“Our strength in clinical translation of non-viral transposon-based CAR-T therapies combined with Pantherna’s proprietary mRNA and LNP-based delivery capabilities allows us to build an efficient engine to expedite clinical development of differentiated in vivo CAR-T assets in cancer, as well as in other indications,” said Ansgar Santel, CEO of Pantherna Therapeutics.